Arch Venture Management is an investment fund managing more than $80.3 billion ran by Mark Mcdonnell. There are currently 8 companies in Mr. Mcdonnell’s portfolio. The largest investments include Verve Therapeutics, Inc. and Erasca, Inc., together worth $49.5 billion.
As of 8th May 2024, Arch Venture Management’s top holding is 2,008,809 shares of Verve Therapeutics, Inc. currently worth over $26.7 billion and making up 33.2% of the portfolio value.
In addition, the fund holds 11,055,554 shares of Erasca, Inc. worth $22.8 billion.
The third-largest holding is Gossamer Bio worth $9.51 billion and the next is Denali Therapeutics Inc worth $7.82 billion, with 381,249 shares owned.
Currently, Arch Venture Management's portfolio is worth at least $80.3 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Arch Venture Management office and employees reside in Chicago, Illinois. According to the last 13-F report filed with the SEC, Mark Mcdonnell serves as the Managing Director, CFO and CAO at Arch Venture Management.
In the most recent 13F filing, Arch Venture Management revealed that it had opened a new position in
Q32 Bio Inc. and bought 320,482 shares worth $5.46 billion.
On the other hand, there are companies that Arch Venture Management is getting rid of from its portfolio.
Arch Venture Management closed its position in Eqrx, Inc. on 15th May 2024.
It sold the previously owned 36,335,375 shares for $80.7 billion.
Mark Mcdonnell also disclosed a decreased stake in Denali Therapeutics Inc by 0.5%.
This leaves the value of the investment at $7.82 billion and 381,249 shares.
The two most similar investment funds to Arch Venture Management are Israel Discount Bank Of New York and Bluegrass Capital Partners L.P.. They manage $80.2 billion and $80.4 billion respectively.
Arch Venture Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 23.6% of
the total portfolio value.
The fund focuses on investments in the United States as
37.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
13% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.4 billion.
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Eqrx, Inc. |
Closed
36,335,375
|
$80,664,533,000 | |
| Verve Therapeutics, Inc. |
No change
2,008,809
|
$26,676,984,000 | 33.23% |
| Erasca, Inc. |
No change
11,055,554
|
$22,774,441,000 | 28.37% |
| Gossamer Bio, Inc. |
No change
8,055,916
|
$9,505,981,000 | 11.84% |
| Denali Therapeutics Inc |
45.05%
381,249
|
$7,823,229,000 | 9.75% |
| Q32 Bio Inc. |
Opened
320,482
|
$5,461,013,000 | 6.80% |
| Cero Therapeutics Holdings, Inc. |
Opened
1,444,296
|
$4,433,989,000 | 5.52% |
| Singular Genomics Systems, Inc. |
No change
3,798,926
|
$1,953,408,000 | 2.43% |
| Unity Biotechnology Inc |
No change
1,004,817
|
$1,647,900,000 | 2.05% |
| No transactions found | |||
| Showing first 500 out of 9 holdings | |||